EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma

Emma W Robinson, Elisabeth A Murphy, Anaseidy Albanez, Sonam Tulsyan iD, Hong Lou, Yi Xie iD, Weiyin Zhou iD, Qian Yang, Tawnjerae Joe, Tongwu Zhang, Jia Liu, Wen Luo und 11 weitere

Cancer Medicine · 2026

DOI: 10.1002/cam4.72228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Emma W Robinson und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Adenocarcinoma, Protein Serine-Threonine Kinases, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical adenocarcinoma accounts for 15%–20% of cervical cancers and is associated with poorer survival and reduced response to screening and immunotherapy compared with squamous cell carcinoma (SCC). The genomic drivers underlying this molecular subgroup remain incompletely characterized. Whole‐exome sequencing was performed on 302 invasive cervical cancers from Guatemala and Venezuela. Structural variation analysis was conducted using SNP‐array and whole‐genome sequencing data. Findings were replicated in more than 4600 additional cervical cancer samples from TCGA, AACR Project GENIE, MSKCC, and Caris datasets. TP53 mutations were more frequent in adenocarcinoma than SCC, particularly in HPV‐negative tumors. STK11 alterations, including mutations and focal deletions, were significantly enriched in HPV‐positive adenocarcinomas compared with SCC and affected 23% of adenocarcinomas overall. Whole‐genome analyses identified recurrent focal deletions, inversions, chromosomal rearrangements, and breakage‐fusion‐bridge events involving chromosome 19p and STK11 that were not detected by exome sequencing alone. STK11 alterations were associated with younger age at diagnosis, poorer overall survival, and inferior outcomes following immune checkpoint inhibitor (ICI) therapy. STK11 alterations significantly co‐occurred with YAP1 amplification but were largely mutually exclusive with PIK3CA mutation. Cervical adenocarcinomas also demonstrated significantly lower CD274 (PD‐L1) expression than SCC. STK11 alterations define a distinct molecular subgroup of cervical adenocarcinoma characterized by structural disruption of chromosome 19p, younger age at onset, and poorer clinical outcomes. These findings have implications for molecular classification and future targeted therapeutic approaches in cervical cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsAdenocarcinomaProtein Serine-Threonine KinasesMutationHumansFemaleAMP-Activated Protein Kinase KinasesExome SequencingMiddle AgedBiomarkers, Tumor

Stichwörter der Autor:innen

STK11 tumor suppressoradenocarcinomacervical cancerhuman papillomaviruswhole exome sequencing

Substanzen

STK11 protein, humanAMP-Activated Protein Kinase KinasesProtein Serine-Threonine KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
  • Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Rockville, Maryland, USA.
  • Caris Life Sciences, Irving, Texas, USA.
  • Instituto de Cancerología (INCAN), Guatemala City, Guatemala.
  • Interdisciplinary Health Program, Northern Arizona University, Flagstaff, Arizona, USA.
  • Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, Maryland, USA.

ORCID-Profile: Sonam Tulsyan, Yi Xie, Weiyin Zhou, Mary Carrington, Roberto Orozco, Michael Dean

Förderung

  • NIH HHS
  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Robinson, E. W., Murphy, E. A., Albanez, A., Tulsyan, S., Lou, H., Xie, Y., Zhou, W., Yang, Q., Joe, T., Zhang, T., Liu, J., Luo, W., Wu, D., Higson, H., Viard, M., Carrington, M., Oberley, M., Morales, H., Mirabello, L., …, & Dean, M. (2026). STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.72228

Vancouver

Robinson EW, Murphy EA, Albanez A, Tulsyan S, Lou H, Xie Y, et al. STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma. Cancer Medicine. 2026. doi:10.1002/cam4.72228

BibTeX
@article{Robinson2026,
  author = {Robinson, Emma W and Murphy, Elisabeth A and Albanez, Anaseidy and Tulsyan, Sonam and Lou, Hong and Xie, Yi and Zhou, Weiyin and Yang, Qian and Joe, Tawnjerae and Zhang, Tongwu and Liu, Jia and Luo, Wen and Wu, Dongjing and Higson, Herbert and Viard, Mathias and Carrington, Mary and Oberley, Matthew and Morales, Hesler and Mirabello, Lisa and Alvirez, Enrique and Orozco, Roberto and Gharzouzi, Eduardo and Dean, Michael},
  title = {STK11 Mutations and Deletions Define an Aggressive Molecular Subgroup of Cervical Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72228}
}
Kostenlos starten →